Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 11/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672068 | 0.79 | MYC (0.63) | MYCMAPTPOLBKDM4EKMT2A | |
| SCHEMBL1672011 | 0.76 | HCRTR1 (0.45) | MYCKDM4E | |
| SCHEMBL8567074 | 0.76 | KMT2A (0.44) | MYCOPRK1MAPTKDM4EKMT2A | |
| SCHEMBL29424909 | 0.74 | MYC (0.41) | MYCKDM4EKMT2A | |
| SCHEMBL30361760 | 0.73 | KDM4E (0.43) | MALT1MYCOPRK1KDM4E | |
| SCHEMBL29424961 | 0.73 | GABRP (0.39) | OPRK1MAPTPOLBTDP1KDM4E | |
| SCHEMBL19480838 | 0.73 | ALDH1A1 (0.39) | MALT1OPRK1MAPTKDM4E | |
| SCHEMBL19472425 | 0.73 | KDM4E (0.43) | MALT1MYCOPRK1KDM4E | |
| SCHEMBL30361654 | 0.73 | ALDH1A1 (0.39) | MALT1OPRK1MAPTKDM4E | |
| SCHEMBL19480698 | 0.73 | KDM4E (0.43) | MAPTPOLBTDP1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240825-B2 | Oxexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| US-20220098165-A1 | OXEXIN 1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-03-31 | — | — | US | disclosed |
| WO-2020157474-A1 | OREXIN 1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157474-A1 | OREXIN 1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098165-A1 | OXEXIN 1 RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, OXTR | MALT1 2073/4885MYC 4583/4885OPRK1 28/4885 |
| US-12240825-B2 | Oxexin 1 receptor antagonists | HCRTR1, HCRTR2, OXTR | MALT1 2073/4885MYC 4583/4885OPRK1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.